1 citations
,
January 2026 in “International Journal of Dermatology” In this case series, three patients with advanced non-small cell lung cancer experienced severe skin eruptions and scarring alopecia after treatment with amivantamab, highlighting the critical need for prompt recognition and management of these adverse effects to minimize treatment interruptions.
3 citations
,
October 2024 in “Cancers” In this study, 37.5% of patients with nodal or metastatic cutaneous melanoma treated with immune checkpoint inhibitors developed skin adverse events, primarily low-grade rashes, vitiligo, and other dermatological symptoms, occurring mainly after 10 weeks of treatment.
9 citations
,
October 2015 in “Cutaneous and ocular toxicology” This case report observed vemurafenib-induced pityriasis amiantacea, a scalp scaling reaction, in a patient with metastatic melanoma, which was managed symptomatically without altering vemurafenib treatment.
4 citations
,
January 2016 in “Dermatology Review” This review focuses on the various skin toxicities caused by chemotherapeutic and targeted tumor therapy drugs, including rashes, keratoacanthoma, and more severe conditions like Stevens-Johnson syndrome, without presenting new clinical results.
26 citations
,
February 2015 in “Pediatric blood & cancer” This study analyzed 19 clinical trials and found that dermatologic adverse events, such as rash, xerosis, and mucositis, frequently occur in pediatric patients receiving targeted anticancer therapies.
